Navigation Links
OncoSec Announces Positive Results from Head & Neck and Breast Cancer Trials
Date:9/26/2011

SAN DIEGO, Sept. 26, 2011 /PRNewswire/ -- OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage OMS ElectroOncology™ therapies to treat solid tumor cancers, announced today clinical study results presented at the Fire, Ice and Beyond: The Future of Ablation Therapies conference in Las Vegas, NV, September 23-24. OncoSec's exhibition highlighted a poster titled, "OMS ElectroChemotherapy: Targeted Ablation of Solid Tumors using Reversible Electroporation in Combination with Bleomycin," which provided preliminary results from their Phase IV head and neck cancer trial and final clinical data from the Phase I breast cancer trials carried out in Europe using OncoSec's OMS ElectroChemotherapy™ treatment approach.

(Logo:  http://photos.prnewswire.com/prnh/20110314/MM64943LOGO)

Phase I Breast Cancer Study

The FDA-approved Phase I study of 13 patients with recurrent breast cancer treated with OncoSec's OMS ElectroChemotherapy™ demonstrated that the therapy was safe, well-tolerated, and achieved a 75% complete tumor response rate.

The open-label, single-treatment trial in patients with recurrent breast cancer following partial or complete mastectomy used intratumoral administration of bleomycin followed by electroporation to significantly enhance uptake of the drug using OMS ElectroChemotherapy™. No treatment-related serious adverse events were observed. Non-serious adverse events were "unremarkable" during a 30-day follow-up period. Thirteen patients (15 tumors) were enrolled in this study.  Excluding one patient lost to follow-up, 10 of the 12 evaluable patients (83%) met the criteria for Complete Response (CR) at 24 weeks.

"The result of this Phase I trial indicates the potential for this local treatment of recurrent breast cancer following partial or complete mastectomy and merits further e
'/>"/>

SOURCE OncoSec Medical Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. OncoSec Medical to Attend 6th Annual Fire, Ice and Beyond: The Future of Ablation Therapies Conference
2. OncoSec Medical to Present at Industry and Investor Conferences
3. OncoSec Medical Appoints Engineering Leader
4. OncoSec Medical Announces the Appointment of Dr. Anthony E. Maida, III, to Its Board of Directors
5. OncoSec Medical Closes Purchase and License Agreement for Tumor Therapy Technology with Inovio Pharmaceuticals
6. OncoSec Medical Closes $1.1M Financing
7. OncoSec Medical to Present at ROTH 23rd Annual Growth Stock Conference
8. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
9. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
10. Uptake Medical Receives CE Mark for InterVapor - Endoscopic Lung Volume Reduction for Treatment of Severe Emphysema - and Announces Positive Clinical Results
11. Delcath Announces Updated Efficacy Results From Phase 3 Trial of Chemosaturation for Melanoma Metastases in the Liver Presented at European Multidisciplinary Cancer Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining ... delivery systems especially for type 1 diabetes ...
(Date:1/15/2014)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") ... its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for ... Solta Medical, Inc. (NASDAQ: SLTM ) ("Solta") ... the seller in cash, without interest (less any required ...
(Date:1/15/2014)... , Jan. 15, 2014 /PRNewswire/ ... market research report is available in ... Global Markets and Technologies for Advanced ... Routes of Administration ... OBJECTIVES A drug delivery ...
Breaking Medicine Technology:Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
... Trial to Examine Safety and Efficacy of DARA ... Pharmacopeia,(Nasdaq: PCOP ), an innovator in ... today announced the initiation of a Phase 2b,clinical ... candidate.,This randomized, double-blind, placebo and active-controlled,parallel-group study is ...
... 29 A study reported in,the journal ... the,Ciliary Neurotrophic Factor gene (CNTF) may affect ... Vanda Pharmaceuticals,Inc., included patients with acute symptoms ... (iloperidone), a novel atypical,antipsychotic agent currently under ...
Cached Medicine Technology:Pharmacopeia Initiates Second Phase 2 Hypertension Study with PS433540 (DARA) 2Pharmacopeia Initiates Second Phase 2 Hypertension Study with PS433540 (DARA) 3Pharmacopeia Initiates Second Phase 2 Hypertension Study with PS433540 (DARA) 4Genetic Variation Associated with Treatment Response in a Clinical Study of a New Atypical Antipsychotic Fiaptatm (iloperidone) 2Genetic Variation Associated with Treatment Response in a Clinical Study of a New Atypical Antipsychotic Fiaptatm (iloperidone) 3
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... first time, researchers at the University of California, San Diego ... processes that power the celebrated health benefits of omega-3 fatty ... be possible to manipulate these processes to short-circuit inflammation before ... it becomes detrimental. The work is published in the ...
... in June,s Journal of Thoracic Oncology says molecular ... be an additional predictive technique for lung cancer screening. ... percent of the positive CT screening results were false positive, ... patients. This research focused on a way to determine if ...
... By Alan Mozes HealthDay Reporter , TUESDAY, May ... a silver bullet when it comes to symptom relief for ... analysis of six prior studies found that the sprays confer ... taken for three weeks at relatively high doses. The ...
... resident Maureen T. Kavanah, MD, an Associate Professor ... (BUSM) and a surgical oncologist at Boston Medical ... Surgical Adjuvant Breast and Bowel Project (NSABP) Distinguished ... and meritorious service to the NSABP in support ...
... for Idiopathic Toe Walking Based on Child,s Age and Severity ... walking pattern, or gait, by age 2. And while some ... the foot or toes, never touching the heel to the ... a neurological disorder. A review article, "Idiopathic Toe Walking," ...
... journal of the American Gastroenterological Association (AGA) Institute, are ... anticipated special 13th issue. Published each May, the 13th ... broad interest; this year,s topic is viral hepatitis. ... PhD, this issue was developed by Gastroenterology,s experts in ...
Cached Medicine News:Health News:Why omega-3 oils help at the cellular level 2Health News:Steroid Nasal Sprays Show Small Benefit for Sinusitis: Study 2Health News:Steroid Nasal Sprays Show Small Benefit for Sinusitis: Study 3Health News:Boston researcher, surgical oncologist receives national award 2Health News:Clinical news alert: Journal of the American Academy of Orthopaedic Surgeons May highlights 2Health News:Gastroenterology special issue focuses on new directions of viral hepatitis care and research 2Health News:Gastroenterology special issue focuses on new directions of viral hepatitis care and research 3
... The new Finnpipette Focus ... specifically to combine ergonomics with ... interchangeable handle plate offers a ... sizes. The new shorter tip ...
500L...
... The new Finnpipette Focus from ... to combine ergonomics with uncompromising ... handle plate offers a custom ... The new shorter tip cones ...
Inquire...
Medicine Products: